On May 9, 2025, biotechnology company Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing. A corporate venture capital firm led the financing round and was joined by new investor BioTrack Capital and existing investors OrbiMed, Creacion Ventures, and Hankang Capital. Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction.

The funding will be used to advance clinical development of the company’s novel siRNA therapeutics for cardiometabolic disorders and continued innovation of its next-generation RNA delivery technologies.

The Wilson Sonsini team that advised Sirius Therapeutics on patent matters related to the transaction included Minyoung Shin, Mike Hostetler, Ying Chen, Jen Zeng, Tiara Wong, and Sarah Ko.

For more information, please see Sirius Therapeutics’ press release.